Sign up online today & collaborate
or click here to find out more
Speaking at the ASCO annual meeting, Leonard Saltz, chief of gastrointestinal oncology at Memorial Sloan Kettering Cancer Center, questioned the cost of new cancer therapies, highlighting studies showing that recent price rises haven't corresponded to increases in the drugs' effectiveness. "These drugs cost too much," Saltz remarked, adding "the unsustainably high prices of cancer drugs is a big problem, and it's our problem."
Saltz focused on the cost of a potential combination regimen comprised of Bristol-Myers Squibb's PD-1 inhibitor Opdivo (nivolumab) and its CTLA-4 inhibitor Yervoy (ipilimumab). Saltz noted that the benefit of the drug combination in patients with advanced melanoma was "truly, truly remarkable for a disease that five years ago we thought was virtually untreatable." However, he said that combining the drugs would cost around $295 000 per patient over nearly one year.For more click here
Source: First word pharma